| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514253030 | Tricyclo ring system having the additional six-membered nitrogen hetero ring as one of the cyclos | 32 |
| 20080221118 | Tetrahydroquinoline Derivatives - Compounds of the formula I, in which s, k, I, W, R | 09-11-2008 |
| 20090036464 | Treatment Of Posterior Capsule Opacification - This invention relates to a method of testing agents, such as sigma ligands for their potential use in treating posterior capsule opacification (PCO). The present invention also relates to the use of sigma ligands, such as sigma-1 antagonists in the manufacture of a medicament for preventing posterior capsule opacification (PCO), as well as methods of treating PCO using sigma ligands. | 02-05-2009 |
| 20090156610 | Spiroindolinone Derivatives - There are provided compounds of the formula | 06-18-2009 |
| 20090163512 | Spiroindolinone Derivatives - There are provided compounds of the formula | 06-25-2009 |
| 20090186901 | CHEMICAL COMPOUNDS - The present invention relates to new heterocyclic compounds of general formula (1) wherein the groups R | 07-23-2009 |
| 20090270411 | PHENANTHRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS - The present invention relates to new phenanthridine derivatives of formula (I), wherein the variables are as defined in the specification, to processes for producing the same, to pharmacological compositions containing the same and to their use in therapy or prevention of painful and inflammatory processes. | 10-29-2009 |
| 20100105696 | IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND mTOR INHIBITORS - The invention relates to the use of compounds of formula (I) | 04-29-2010 |
| 20100317672 | Monomaleate Monohydrate Salt of a 5HT1A Receptor Antagonist - The present invention relates to a monomaleate monohydrate salt of 7-methyl-6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4,5-dihydroimidazo[1,5-a]quinoline-3-carboxamide, uses of the salt as a medicament in the treatment of sexual dysfunction and pharmaceutical compositions and dosage forms comprising the salt. | 12-16-2010 |
| 20110105521 | COMBINATION OF (A) A PHOSPHOINOSITIDE 3-KINASE INHIBITOR AND (B) A MODULATOR OF RAS/RAF/MEK PATHWAY - The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound and (b) a compound which modulates the Ras/Raf/Mek pathway for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human. | 05-05-2011 |
| 20110136821 | Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase Type 1 - This invention relates to novel compounds of the Formulae I or II and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD 1 in mammals. Formula (I). | 06-09-2011 |
| 20110281887 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER - The present invention is directed to methods of use of a compound of Formula I: | 11-17-2011 |
| 20120071493 | SUBSTITUTED 8-SULFONYL-2,3,4,5-TETRAHYDRO-1H-GAMMA-CARBOLINES, LIGANDS AND PHARMACEUTICAL COMPOSITION; METHOD FOR THE PRODUCTION AND USE OF SAME - The invention relates to novel substituted 8-sulfonyl-2,3,4,5-tetrahydro-1H-γ-carbolines of the general formula 1 and their pharmaceutically acceptable salt—ligands exhibiting biological activity simultaneously towards alpha-adrenoceptors, dopamine receptors, histamine receptors, imidazoline receptors, sigma receptors, norepinefrine receptors, serotonin receptors, to active components, pharmaceutical compositions, comprising as an active component novel ligands, to novel medicaments intended for treatment of conditions and diseases of central nervous system. In the general formula 1 | 03-22-2012 |
| 20120077820 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER - The present invention is directed to methods of use of a compound of Formula I: | 03-29-2012 |
| 20120095016 | THERAPEUTIC 5,6,5-TRICYCLIC ANALOGS - The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABA | 04-19-2012 |
| 20120157469 | PIPERAZINONE-SUBSTITUTED TETRAHYDRO-CARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF - The present invention relates to piperazinone-substituted tetrahydro-carboline derivatives of formula (I): | 06-21-2012 |
| 20120302580 | OPTICALLY ACTIVE COMPOUND OF PRULIFLOXACIN FOR TREATING INFECTION AND PREPARATION METHOD THEREOF - Anti-infection levorotatory optically active compound (S-configuration) of prulifloxacin represented by the following formula (1) and preparation method thereof are disclosed. Said method utilizes levorotatory ulifloxacin as the raw material and the reaction is conducted in organic solvent in the presence of alkaline materials, wherein the reaction temperature is −20° C.˜60° C. and the reaction time is 15 minutes to 24 hours. | 11-29-2012 |
| 20130040959 | Heterocyclic Quinolizine Derived M1 Receptor Positive Allosteric Modulators - The present invention is directed to novel 3-oxo-2,3-dihydropyrazolo[4,3-c]quinolizine derived compounds of generic formula (I) or a pharmaceutically acceptable salt thereof, which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. | 02-14-2013 |
| 20130079352 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE - This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[3,4-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 03-28-2013 |
| 20130109699 | TETRAHYDROCARBOLINE DERIVATIVE | 05-02-2013 |
| 20130131077 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE - This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[3,4-b]indoles are described, as are pharmaceutical-compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 05-23-2013 |
| 20130165449 | Compounds and Method for Treatment of Cancer - The present invention is directed to methods of use of a compound of Formula I: | 06-27-2013 |
| 20130178479 | PHARMACEUTICAL COMBINATIONS - The present invention relates to a pharmaceutical combination which comprises (a) an mTOR catalytic inhibitor, such as a catalytic phosphatidylinositol-3-kinase (PI3K) and mTOR inhibitor compound which is an imidazoquinoline derivative and (b) at least one allosteric mTOR inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of an mammalian target of rapamycin (mTOR) kinase dependent proliferative diseases; and the uses of such a combination in the treatment of mTOR kinase dependent proliferative diseases; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human. | 07-11-2013 |
| 20130190322 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES - This disclosure is directed to pyrido[4,3-b]indoles having rigid moieties. The compounds in one embodiment are pyrido[4,3-b]indoles having an unsaturated hydrocarbon moiety. The compounds in another embodiment are pyrido[4,3-b]indoles having a cycloalkyl, cycloalkenyl or heterocyclyl moiety. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 07-25-2013 |
| 20130190323 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE - This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[3,4-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 07-25-2013 |
| 20130203769 | Targeting Metabolic Adaptive Responses to Chemotherapy - Methods for targeting adaptive responses to chemotherapy are described. In various embodiments, a method comprises administering at least one compound that inhibits S6K1, mTORC, or upstream or downstream pathway components of S6K1 or mTORC, in association with administration of at least one antagonist of PPARα, PPARδ, or PGC1α. In various embodiments, the compound that inhibits S6K1, mTORC, or upstream or downstream pathway components of S6K1 or mTORC is rapamycin, everolimus, temsirolimus, or imatinib. The antagonist of PPARα, PPARδ, or PGC1α can be GW7647, GW6471, GW501516, GSK3787, or GSK0660. | 08-08-2013 |
| 20140315916 | MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF - The present invention provides a compound of Formula (1): as described herein or a pharmaceutically acceptable salt or solvate thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same. | 10-23-2014 |
| 20150051218 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES - This disclosure is directed to pyrido[4,3-b]indoles having rigid moieties. The compounds in one embodiment are pyrido[4,3-b]indoles having an unsaturated hydrocarbon moiety. The compounds in another embodiment are pyrido[4,3-b]indoles having a cycloalkyl, cycloalkenyl or heterocyclyl moiety. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 02-19-2015 |
| 20160000778 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION - An exemplary embodiment relates to novel protein modulators capable of altering function of the mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction. An exemplary embodiment provides compositions, pharmaceutical preparations and methods of correcting the cellular alteration of a mutant CFTR protein wherein the CFTR mutation is a mutation ΔF508-CFTR, or another mutation of class II. | 01-07-2016 |
| 20160024078 | CaMKII INHIBITORS AND USES THEREOF - The present invention provides compounds useful as inhibitors of Ca | 01-28-2016 |
| 20160137607 | Autophagy Inhibitors - The present invention relates to compounds of formulas III and V that are useful as pharmaceutical agents, particularly as autophagy inhibitors. | 05-19-2016 |
| 20160152610 | Carboline Compounds Usable in The Treatment of Neurodegenerative Diseases | 06-02-2016 |
| 20160194317 | T-BOX RIBOSWITCH-BINDING ANTI-BACTERIAL COMPOUNDS | 07-07-2016 |
